{
    "clinical_study": {
        "@rank": "39992", 
        "arm_group": [
            {
                "arm_group_label": "Group A", 
                "arm_group_type": "Other", 
                "description": "First periody: Heparin Test Drug (Blau Farmac\u00eautica S/A)\nSecundy periody: Heparin Comparator Drug (APP Pharmaceuticals)"
            }, 
            {
                "arm_group_label": "Group B", 
                "arm_group_type": "Other", 
                "description": "First periody: Heparin Comparator Drug (APP Pharmaceuticals)\nSecundy periody: Heperin Test Drug (Blau Farmac\u00eautica S/A)"
            }
        ], 
        "brief_summary": {
            "textblock": "The objective of this clinical, randomized, crossover, is to assess the pharmacodynamic\n      profile of the drug Heparin Sodium from swine (intravenously), manufactured and marketed by\n      Laboratory Blau Farmac\u00eautica S/A, compared to the product of Heparin Sodium \u00ae company APP\n      Pharmaceuticals, through the determination of activity of the following markers:\n\n        -  Anti-FXa;\n\n        -  Anti-FIIA."
        }, 
        "brief_title": "PHARMACODYNAMICS ASSESSMENT PRODUCT HEPARIN SODIUM (INTRAVENOUSLY) OF THE SWINE 5.000UI/ML OF BLAU FARMAC\u00caUTICA S/A IN HEALTHY SUBJECTS IN COMPARISON OF SODIUM HEPARIN APP PHARMACEUTICALS", 
        "completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "The pharmacodynamic profile of the drug will be assessed through:\n\n        -  Reason for Anti-FXa activity / Anti-FIIA;\n\n        -  TFPI activity.\n\n      The aPTT activity marker will be evaluated as an exploratory objective."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  a) Confirm the voluntary participation and agree to all the purposes of the study by\n             signing and dating the IC in two ways; b) Being male, aged between 18 and 55 years\n             old and clinically healthy; c) BMI \u2265 18.5 and \u2264 30.\n\n        Exclusion Criteria:\n\n          -  a) Participation in clinical trials in the 12 months preceding the survey; b)\n             Presence of pulmonary diseases, cardiovascular, neurological, endocrine,\n             gastrointestinal, genitourinary or other systems; c) acute illness in the period up\n             to 07 days before the beginning of the study; d) determining Chronic administration\n             of medications, such as hypertension, diabetes or any other that requires continued\n             use of any drug; e) Hemoglobin <13 g / dL; f) Continuous use of oral anticoagulants,\n             platelet inhibitors or anti-inflammatory; g) Use of medications that interact with\n             heparin (see Section 7.8.1); h) history of gastrointestinal bleeding, deep vein\n             thrombosis or pulmonary embolism; i) History of coagulopathy and bleeding diathesis;\n             j) Presence of bruises on physical examination. k) Changes in skin or subcutaneous\n             tissue of the place where the injection is made \u200b\u200b(eg liposuction in the abdomen).\n\n             l) absolute platelet count below 100 x 109 / L; m) A history of acute haemorrhage in\n             the last 30 days; n) history of sensitivity to biological products derived from\n             mammalian albumin or any component of the formulation;\n\n             a) history of allergy or major disease Steven Johnson; p) History of present use or\n             there are at least 12 months of tobacco; q) current or previous history (less than 12\n             months) of illicit drug use;"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "55 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 25, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651923", 
            "org_study_id": "HEPBLA0312IV-I", 
            "secondary_id": "Vers\u00e3o 01 - 15/03/2012"
        }, 
        "intervention": {
            "arm_group_label": [
                "Group A", 
                "Group B"
            ], 
            "description": "Whereas it will be a crossover study with two periods, each drug will be administered only once, at a dose of 5.000UI. In each period, the drug will be administered intravenously.", 
            "intervention_name": "Heparin", 
            "intervention_type": "Drug", 
            "other_name": [
                "Sodium heparin (Blau Farmac\u00eautica S/A)", 
                "Sodium heparin (App Pharmaceuticals)"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Calcium heparin", 
                "Heparin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "subjects", 
        "lastchanged_date": "August 10, 2012", 
        "location": {
            "contact": {
                "email": "alexandre@lalclinica.com.br", 
                "last_name": "Alexandre Frederico, physician", 
                "phone": "+ 55 19 3871-6399"
            }, 
            "facility": {
                "address": {
                    "city": "Valinhos", 
                    "country": "Brazil", 
                    "state": "S\u00e3o Paulo", 
                    "zip": "13276245"
                }, 
                "name": "LAL Cl\u00ednica Pesquisa e Desenvolvimento Ltda."
            }, 
            "investigator": {
                "last_name": "Alexandre Frederico, physician", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "2", 
        "overall_contact": {
            "email": "alexandre@lalclinica.com.br", 
            "last_name": "Alexandre Frederico, physian", 
            "phone": "+ 55 19 3871-6399"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood samples", 
            "measure": "Pharmacodynamic of activity of markers: Anti-Fxa and Anti-FIIA", 
            "safety_issue": "Yes", 
            "time_frame": "0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651923"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Blood samples", 
            "measure": "Pharmacodynamic of the ratio between the activity Anti-FXa/Anti-FIIa and the activity of TFPI and TTPa", 
            "safety_issue": "Yes", 
            "time_frame": "TFPI: 0:20, 0:10 before administration and 0:10, 0:20, 0:30, 0:45, 1, 1:30, 2, 2:30, 3, 3:30, 4, 4:30 , 5, 6, 8, 12 and 24 hours after drug administration. TTPa: 0:20, 0:10 before administration and 1 h, 4h, 8h, 12h and 24h after drug administration"
        }, 
        "source": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "L.A.L Clinica Pesquisa e Desenvolvimento Ltda.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Crossover Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}